Browse
Submit Data
Databases
API
Help

Dataset Information

7 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Association between adverse events and prognosis in postoperative adjuvant chemotherapy for colorectal cancer

ABSTRACT: Primary outcome(s): Relapse-free survival Overall survival Adverse event Compliance

DISEASE(S): Colorectal Cancer

PROVIDER: 2740981 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Postoperative complications of colorectal cancer and their impact on postoperative adjuvant chemotherapy and prognosis

Project description:Primary outcome(s): overall survival relapse-free survival disease-free survival Time-to-treatment-failure Compliance Relative Dose Intensity Percentage of drug treatment discontinuation, dose reduction and drug suspension

| 2725003 | ecrin-mdr-crc

Usefulness of remote monitor system for adverse events in outpatient receiving cancer chemotherapy for colorectal cancer

Project description:Primary outcome(s): The incidence of Grade >=2 hand-foot syndrome (Relapse-Free survival(RFS))

| 104238 | ecrin-mdr-crc

Musculoskeletal adverse events associated with adjuvant aromatase inhibitors.

Project description: Not available

| S-EPMC2943085 | biostudies-literature

Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes.

Project description: Not available

| S-EPMC5127223 | biostudies-other

Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia

Project description:Metaphase karyotyping is an established diagnostic standard in acute myeloid leukemia (AML) for risk stratification. One of the cytogenetic findings in AML are structurally highly abnormal marker chromosomes. In this study, we have assessed frequency, cytogenetic characteristics, prognostic impact and underlying biological origin of marker chromosomes. Given their inherent gross structural chromosomal damage, we speculated that they may arise from chromothripsis, a recently described phenomenon of chromosome fragmentation in a single catastrophic event. In 2 large consecutive prospective, randomized, multicenter, intensive chemotherapy trials (AML96, AML2003) from the Study Alliance Leukemia (SAL), marker chromosomes were detectable in 165/1026 (16.1%) of aberrant non-core-binding-factor (CBF) karyotype patients. Adverse-risk karyotypes displayed a higher frequency of marker chromosomes (26.5% in adverse-risk, 40.3% in complex aberrant and 41.2% in abnormality(17p) karyotypes, p<.0001 each). Marker chromosomes were associated with a poorer prognosis compared to other non-CBF aberrant karyotypes and led to lower remission rates (CR+CRi), inferior event-free survival as well as overall survival in both trials. In multivariate analysis, marker chromosomes independently predicted poor prognosis in the AML96 trial ≤60 years. As detected by array-CGH, about one third of marker chromosomes (18/49) had arisen from chromothripsis, whereas this phenomenon was virtually undetectable in a control group of marker chromosome-negative complex aberrant karyotypes (1/34). The chromothripsis-positive cases were characterized by a particularly high degree of karyotype complexity and dismal prognosis. In conclusion, marker chromosomes are indicative of chromothripsis and associated with poor prognosis per se and not merely by association with other adverse cytogenetic features.

2017-03-29 | GSE93886 | GEO

Association between antihypertensive treatment and adverse events: systematic review and meta-analysis.

Project description: Not available

| S-EPMC7873715 | biostudies-literature

Association Between Parent Comfort With English and Adverse Events Among Hospitalized Children.

Project description: Not available

| S-EPMC7573792 | biostudies-literature

Transcription profiling by array of diagnosis and relapse specimens of paediatric patients with acute lymphoblastic leukaemia (ALL) to identify mechanisms and pathways of therapy failure

Project description:Gene expression profiles were compared between diagnosis and relapse specimens of paediatric patients with acute lymphoblastic leukaemia (ALL) to identify mechanisms and pathways of therapy failure. The following descriptions provide further information on the annotations applied in this submission: Day 7 MRD- Minimal residual disease (MRD) measured at Day 7 after treatment initiation. Day 14 MRD- MRD measured at day 14 after treatment initiation. End of Induction MRD- MRD at the end of remission induction therapy. Event- Clinical event that is used to interpret patient outcome and used to determine relapse status. Relapse status- The relapse status of the patient which is used to model kaplan-meier survival curves in the related manuscript. Status 0 indicates non-relapse status (patient didn't relapse within time monitored), and 1 indicates relapse. Relapse-Free Survival- The length of time that the patients were relapse-free, or the length of time they were studied for, if they did not relapse. Paired Specimen- Many of the specimens in this study were diagnosis and relapse specimens from the same patient (i.e. Specimens taken at different times). This factor indicates which of the specimens were matched to each other in this way i.e. Which came from the same patient.

2012-07-13 | E-MTAB-1216 | biostudies-arrayexpress

The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis.

Project description: Not available

| S-EPMC7758867 | biostudies-literature

Prognosis for Stage I/II NSCLC

Project description:Eighty-four completely resected stage I/II non-small cell lung cancer (NSCLC) without adjuvant therapy were profiled using whole genome expression microarrys in order to identify novel classifications associated with RFS. Association with relapse-free survival (RFS) and clinicopathological parameters was assessed. An external cohort of 162 tumors was used to validate results.

2014-07-29 | E-MTAB-1790 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data